Abstract
Polyclonal activation of developing B cells is an injurious process, because most of these cells are nontolerant and express autoreactive receptors. CpG DNA is a polyclonal activator of mature B cells, but its effect on developing B cells is unclear. We tested whether developing, nontolerant B cells are responsive to mitogenic stimulation by CpG DNA and whether such a stimulus can interfere with the establishment of central tolerance. We found that developing B cells express Toll-like receptor 9 and undergo a polyclonal response to CpG DNA stimulation, as revealed by proliferation and differentiation to antibody-producing cells. In vitro and ex vivo experiments revealed that stimulation with CpG DNA protects immature B cells from negative selection imposed by apoptosis and receptor editing and results in the production of autoantibodies. Finally, we found that in vivo administration of CpG DNA activates immature B cells in the bone marrow and suppresses the expression of recombination-activating genes in a mouse model of central tolerance and receptor editing. These results suggest that mitogenic signals provided by CpG DNA stimulate nontolerant immature B cells in the bone marrow and have the potential to interfere with central tolerance.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacology
-
Apoptosis / drug effects
-
Autoimmunity / drug effects
-
Autoimmunity / immunology
-
B-Lymphocytes / drug effects
-
B-Lymphocytes / immunology*
-
B-Lymphocytes / metabolism
-
Bone Marrow / drug effects
-
Bone Marrow / immunology*
-
Bone Marrow Cells / drug effects
-
Bone Marrow Cells / immunology
-
Bone Marrow Cells / metabolism
-
Cell Differentiation / drug effects
-
Cell Differentiation / immunology
-
Cell Proliferation / drug effects
-
Cells, Cultured
-
DNA-Binding Proteins / metabolism
-
Gene Expression / drug effects
-
Immunoglobulin M / metabolism
-
Leukocyte Common Antigens / metabolism
-
Lymphocyte Activation / drug effects
-
Lymphocyte Activation / immunology*
-
Membrane Glycoproteins / metabolism
-
Mice
-
Mice, Inbred C57BL
-
Mice, Inbred Strains
-
Mice, Transgenic
-
NF-kappa B / metabolism
-
Oligodeoxyribonucleotides / pharmacology*
-
Proto-Oncogene Proteins c-myc / metabolism
-
Receptors, Antigen, B-Cell / immunology
-
Receptors, Complement / metabolism
-
Toll-Like Receptor 9 / genetics
-
Toll-Like Receptor 9 / metabolism
Substances
-
Antibodies, Monoclonal
-
CPG-oligonucleotide
-
DNA-Binding Proteins
-
Immunoglobulin M
-
Membrane Glycoproteins
-
NF-kappa B
-
Oligodeoxyribonucleotides
-
Proto-Oncogene Proteins c-myc
-
Rag2 protein, mouse
-
Receptors, Antigen, B-Cell
-
Receptors, Complement
-
Tlr9 protein, mouse
-
Toll-Like Receptor 9
-
complement 1q receptor
-
Leukocyte Common Antigens